Intensity Therapeutics, Inc.(INTS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INTS Intensity Therapeutics, Inc.

交易中 03-23 15:51:44 EDT

6.08

+0.10

+1.67%

最高6.11	最低5.91	成交量1.70万
今开5.93	昨收5.98	日振幅3.34%
总市值1,541万	流通市值1,410万	总股本253.39万
成交额10.22万	换手率0.73%	流通股本231.92万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":6.08,"timestamp":1774295311802,"preClose":5.98,"halted":0,"volume":16974,"delay":0,"changeRate":0.016722408026755793,"floatShares":2319200,"shares":2533900,"eps":-12.785525,"marketStatus":"交易中","change":0.1,"latestTime":"03-23 15:51:44 EDT","open":5.93,"high":6.11,"low":5.91,"amount":102188.198772,"amplitude":0.033445,"askPrice":6.24,"askSize":500,"bidPrice":6.04,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-12.785525,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":5.98,"preHourTrading":{"tag":"盘前","latestPrice":5.89,"preClose":5.98,"latestTime":"09:16 EDT","volume":2991,"amount":18463.939506,"timestamp":1774271770297,"change":-0.09,"changeRate":-0.01505,"amplitude":0.051839},"postHourTrading":{"tag":"盘后","latestPrice":5.98,"preClose":5.98,"latestTime":"19:03 EDT","volume":4705,"amount":28131.488,"timestamp":1774047830985,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.581987},"requestUrl":"/m/hq/s/INTS","defaultTab":"news","newsList":[{"id":"1192107848","title":"Intensity Therapeutics公司初步Invincible-4研究显示：INT230-6联合标准疗法病理完全缓解率达71.4%，单独标准疗法为33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192107848","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192107848?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:34","pubTimestamp":1773315250,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics公司公布的Invincible-4初步研究数据揭示显著疗效差异：在接受其核心候选药物INT230-6与标准疗法联合治疗的患者组中，病理完全缓解率高达71.4%，而仅接受标准疗法对照组的缓解率则为33%。这一数据凸显了INT230-6在联合用药方案中的巨大治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"1167962781","title":"Intensity Therapeutics公司提议修改方案：降低药物剂量并采用单次Int230-6注射","url":"https://stock-news.laohu8.com/highlight/detail?id=1167962781","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167962781?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:32","pubTimestamp":1773315132,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics公司近日提出一项方案修订，计划减少药物使用量并改为单次注射Int230-6。这一调整旨在优化治疗方案，可能提升患者的治疗体验并降低潜在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"1166093020","title":"Intensity Therapeutics, Inc. 公布其二期术前三阴性乳腺癌Invincible-4研究最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1166093020","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166093020?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:31","pubTimestamp":1773315077,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. 近期发布了关于其正在进行的二期临床试验——Invincible-4研究的最新信息。该研究主要针对术前三阴性乳腺癌患者，旨在评估新型疗法的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"1179255947","title":"Intensity Therapeutics公司计划提交Invincible-4研究方案修正案 拟于2026年第一季度重启患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1179255947","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179255947?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:50","pubTimestamp":1768308626,"startTime":"0","endTime":"0","summary":"生物医药公司Intensity Therapeutics, Inc.近日宣布，将对其关键临床试验Invincible-4的研究方案进行修订，并计划在2026年第一季度重新启动患者招募工作。这一战略调整旨在优化试验设计，提升试验效率，为后续研发进程奠定更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"1128082733","title":"Intensity Therapeutics获180天延长期限以恢复符合纳斯达克最低报价要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1128082733","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128082733?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:31","pubTimestamp":1764937870,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics获180天延长期限以恢复符合纳斯达克最低报价要求","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"1146466508","title":"Intensity Therapeutics在2025年圣安东尼奥乳腺癌论坛上宣布两场演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=1146466508","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146466508?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:48","pubTimestamp":1764852512,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics在2025年圣安东尼奥乳腺癌论坛上宣布将进行两场演讲。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"1135463394","title":"Intensity Therapeutics, Inc. 宣布400万美元普通股注册直接发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1135463394","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135463394?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:01","pubTimestamp":1761912117,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. 宣布400万美元普通股注册直接发行定价","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2579107001","title":"癌症候选药物1/2期临床数据积极，Intensity Therapeutics(INTS.US)股价暴涨395%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107001","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579107001?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:09","pubTimestamp":1761869380,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，市值约1300万美元的生物制药公司Intensity Therapeutics，周四公布其转移性或难治性癌症候选药物INT230-6的1/2期临床试验结果后，股价收盘暴涨近395%。疾病控制率达75%。合作研发进展上，Intensity Therapeutics已与默沙东及百时美施贵宝公司达成合作，分别探索INT230-6与Keytruda、Yervoy的联合用药方案。公司将于美国东部时间10月31日上午9点召开电话会议，讨论本次临床试验结果。该结果已发表于学术期刊《eBioMedicine》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","INTS","BK4539","LENZ","BK4139"],"gpt_icon":1},{"id":"1151054554","title":"Intensity Therapeutics, Inc. 发布关于 Int230-6 治疗转移性或难治性癌症的临床结果于《Ebiomedicine》期刊","url":"https://stock-news.laohu8.com/highlight/detail?id=1151054554","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151054554?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:31","pubTimestamp":1761823870,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. 发布关于 Int230-6 治疗转移性或难治性癌症的临床结果于《Ebiomedicine》期刊","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2518275867","title":"Intensity Therapeutics, Inc.盘中异动 股价大涨9.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518275867?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:25","pubTimestamp":1741616707,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时25分，Intensity Therapeutics, Inc.股票出现波动，股价急速拉升9.50%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222507a26a395a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222507a26a395a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2517288129","title":"Intensity Therapeutics, Inc.盘中异动 下午盘股价大涨7.24%报2.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517288129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517288129?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:25","pubTimestamp":1741199118,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时25分，Intensity Therapeutics, Inc.股票出现波动，股价快速拉升7.24%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.34%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022518a26107d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022518a26107d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INTS","BK4139","LENZ"],"gpt_icon":0},{"id":"2516630537","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大跌6.41%报2.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630537?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:51","pubTimestamp":1741013463,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时51分，Intensity Therapeutics, Inc.股票出现异动，股价快速下挫6.41%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225103abe639c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225103abe639c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","INTS"],"gpt_icon":0},{"id":"2514090924","title":"Intensity Therapeutics, Inc.盘中异动 股价大涨8.68%报2.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090924?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:33","pubTimestamp":1740494019,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时33分，Intensity Therapeutics, Inc.股票出现异动，股价大幅上涨8.68%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为760.40%、469.26%、243.33%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp、Dominari Holdings Inc.，振幅分别为20.51%、14.67%、11.73%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522333998924d2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522333998924d2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INTS","LENZ","BK4139"],"gpt_icon":0},{"id":"2513227057","title":"Intensity Therapeutics, Inc.盘中异动 早盘大幅拉升7.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513227057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513227057?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:32","pubTimestamp":1740407559,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时32分，Intensity Therapeutics, Inc.股票出现异动，股价大幅上涨7.17%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242232399890f5c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242232399890f5c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2512165996","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大涨8.06%报2.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165996?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:37","pubTimestamp":1739889460,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时37分，Intensity Therapeutics, Inc.股票出现波动，股价快速上涨8.06%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182237409889fe1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182237409889fe1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INTS","LENZ","BK4139"],"gpt_icon":0},{"id":"2511696256","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大涨7.37%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511696256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511696256?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:39","pubTimestamp":1739543980,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时39分，Intensity Therapeutics, Inc.股票出现异动，股价大幅拉升7.37%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422394196231d4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422394196231d4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INTS","LENZ"],"gpt_icon":0},{"id":"2511252075","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大涨7.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511252075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511252075?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:38","pubTimestamp":1739457481,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时38分，Intensity Therapeutics, Inc.股票出现波动，股价急速上涨7.51%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223801a244acc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223801a244acc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INTS","BK4139","LENZ"],"gpt_icon":0},{"id":"2510518866","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大涨10.90%报2.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510518866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510518866?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:32","pubTimestamp":1739197934,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时32分，Intensity Therapeutics, Inc.股票出现波动，股价快速上涨10.90%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223214a240a224&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223214a240a224&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","INTS","BK4139"],"gpt_icon":0},{"id":"2509774952","title":"Intensity Therapeutics, Inc.盘中异动 快速跳水5.11%报2.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774952","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509774952?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分，Intensity Therapeutics, Inc.股票出现波动，股价大幅跳水5.11%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。Intensity 的候选产品有可能诱导适应性全身免疫反应，不仅攻击注射的肿瘤，还攻击非注射的肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223230abc4d4c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223230abc4d4c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","INTS","BK4139"],"gpt_icon":0},{"id":"2508992457","title":"Intensity Therapeutics, Inc.盘中异动 早盘股价大涨6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508992457","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508992457?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:31","pubTimestamp":1738679489,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时31分，Intensity Therapeutics, Inc.股票出现异动，股价大幅拉升6.51%。Intensity Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Azitra Inc、Evaxion Biotech As、Achilles Therapeutics Plc Ads Each Repr 1 Share Spon涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为834.81%、673.74%、185.13%，振幅较大的相关个股有Omega Therapeutics, Inc.、Azitra Inc、Evaxion Biotech As，振幅分别为17.57%、13.82%、8.75%。Intensity Therapeutics, Inc.公司简介：Intensity Therapeutics Inc 是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223130987a4a5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223130987a4a5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INTS","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intensitytherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.118},{"period":"1month","weight":-0.0241},{"period":"3month","weight":-0.4172},{"period":"6month","weight":-0.037},{"period":"1year","weight":-0.8761},{"period":"ytd","weight":-0.4169}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intensity Therapeutics, Inc.于2012年11月30日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，开创了一种新的基于免疫的方法来治疗实体瘤癌症。该公司利用其DfuseRx技术平台创造专利药物配方，直接注射后迅速扩散到整个肿瘤，并将治疗剂扩散到癌细胞中。该公司的候选产品有可能诱导一种适应性免疫反应，不仅可以攻击注射的肿瘤，还可以攻击未注射的肿瘤。该公司的主要候选产品INT230-6正在开发中，用于治疗实体瘤患者，如肉瘤和乳腺癌患者。","exchange":"NASDAQ","name":"Intensity Therapeutics, Inc.","nameEN":"Intensity Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intensity Therapeutics, Inc.(INTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intensity Therapeutics, Inc.(INTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intensity Therapeutics, Inc.,INTS,Intensity Therapeutics, Inc.股票,Intensity Therapeutics, Inc.股票老虎,Intensity Therapeutics, Inc.股票老虎国际,Intensity Therapeutics, Inc.行情,Intensity Therapeutics, Inc.股票行情,Intensity Therapeutics, Inc.股价,Intensity Therapeutics, Inc.股市,Intensity Therapeutics, Inc.股票价格,Intensity Therapeutics, Inc.股票交易,Intensity Therapeutics, Inc.股票购买,Intensity Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intensity Therapeutics, Inc.(INTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intensity Therapeutics, Inc.(INTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}